78 Years of Galenika: Firm and Sustainable Business Growth

In the first half of 2023, pharmaceutical company Galenika recorded constant growth in all business segments, both in Serbia and in the regional and international markets where it operates. Since the beginning of the year, Galenika has registered as many as 47 new products in Serbia and the region, while 29 products have been put on the market. In Serbia, sales increased by 10%, and in countries in the region by as much as 14%. In addition to the countries in the region, the company operates in 16 international markets on three continents, while it increased exports to the EU market by 40%, where it launched 22 products so far. Compared to the first half of last year, the production of Galenika's range of products has increased by 7%, company has 37 brands in the leading positions in their categories in terms of market share in Serbia in the first half of the year 2023. 

With a strategic partnership with its sister company from Brazil - EMS, since the beginning of the year, Galenika has successfully implemented technology transfer for 6 products from the newer generation of generic drugs and started preparation for another 5. 

„In 2023 we are marking 78 years and we are strongly focused on the future. We integrate the most valuable from the past and the present, with full dedication to investments, innovation and sustainable growth. Quality is our first priority – both in products and everything we do. We are the holder of 15 domestic and international GMP and ISO certificates for the highest level of work and production standards. We are strategically committed to constantly expanding our product portfolio for the benefit of consumers. The recognition of the Galenika brand, in which consumers have confidence, is strongly transferred to new international markets“, said Ricardo Vian Marques, CEO of Galenika. 

You can read the whole news here.